Results 131 to 140 of about 35,110 (216)

Natural killer (NK) cells and their involvement in different types of cancer. Current status of clinical research [PDF]

, 2017
Natural killer cells are the main agents of innate immunity. Since 1970, various studies have repeatedly confirmed their involvement in decreasing local tumor growth and also decreasing the risk of metastasis, due to their cytotoxic effects and also ...
Moldovan, Adina D., Tanase, Cristiana, Zaharescu, Isadora   +2 more
core   +4 more sources

Exploration of Proteins Involved in Acquisition of Resistance to Cetuximab

Indonesian Journal of Pharmaceutics, 2019
Anti-epidermal growth factor receptor (EGFR) monoclonal antibodies (Mabs) show high efficacy in about 50% of colorectal cancer (CRC) patients with wild-type KRAS. However, < 20% of patients with KRAS wild-type CRC have continued therapeutic effects with these agents, and acquired resistance to treatment has become a serious clinical problem. In this
Hironori Nakamura, Ayumu Nagamine, Hideaki Yashima, Takuya Araki, Koujirou Yamamoto   +4 more
openaire   +2 more sources

Extracellular and Membrane Protein: Structure, Biological Functions, Diseases, and an Emerging Modality for Drug Discovery

MedComm, Volume 7, Issue 4, April 2026.
Targeted protein degradation represents a paradigm shift from traditional protein inhibition to complete protein elimination. This is achieved through three main strategies for degrading extracellular and membrane proteins: recruitment of cell‐surface LTRs, engagement of intracellular proteins, and receptor‐independent mechanisms.
Mengqing Zhao, Wenhao Yin, Jianjian Han, Huimin Wang, Zheng Liu, Lilong Liu, Wuxiang Mao   +6 more
wiley   +1 more source

Sym004, a Novel EGFR Antibody Mixture, Can Overcome Acquired Resistance to Cetuximab

Neoplasia: An International Journal for Oncology Research, 2013
The epidermal growth factor receptor (EGFR) is a central regulator of tumor progression in a variety of human cancers. Cetuximab is an anti-EGFR monoclonal antibody that has been approved for head and neck and colorectal cancer treatment, but many ...
Mari Iida, Toni M Brand, Megan M Starr, Chunrong Li, Evan J Huppert, Neha Luthar, Mikkel W Pedersen, Ivan D Horak, Michael Kragh, Deric L Wheeler   +9 more
doaj   +1 more source

Determining the Survival Impact and Cost‐Effectiveness of Multi‐Gene Panel Sequencing in Metastatic Colorectal Cancer With Super Learning Approaches

Health Services Research, Volume 61, Issue 2, April 2026.
ABSTRACTObjectiveTo determine the effectiveness and cost‐effectiveness of multi‐gene panel sequencing compared to single‐gene KRAS testing for metastatic colorectal cancer (mCRC).Study Setting and DesignBritish Columbia, Canada (BC) is a provincial single‐payer public healthcare system, and it was the first province to publicly reimburse multi‐gene ...
Emanuel Krebs, Deirdre Weymann, Howard J. Lim, Stephen Yip, Dean A. Regier   +4 more
wiley   +1 more source

Clinical Applications of Phosphoproteomics: Illuminating Cancer Signaling and Enabling Rational Therapeutic Strategies

Cancer Science, Volume 117, Issue 4, Page 885-895, April 2026.
Mass spectrometry‐based phosphoproteomics for mechanistic dissection of cancer signaling pathways and uncovering therapeutic vulnerabilities. ABSTRACT Protein phosphorylation is a central post‐translational modification regulating cellular signaling, frequently dysregulated in cancer.
Hirokazu Shoji, Narikazu Boku, Jun Adachi   +2 more
wiley   +1 more source

Self‐Immolative Systems in Diagnostic and Therapeutic Applications

ChemMedChem, Volume 21, Issue 5, 13 March 2026.
Self‐Immolative Systems enable the precise, residue‐free release of active molecules, drugs, probes, or sensors, via cyclization or elimination, triggered by specific stimuli. Their versatility drives advances in drug delivery, diagnostics, nanotechnology, materials chemistry, and biosensing, offering chemists control over molecular activation and ...
Windbedema Prisca Ouédraogo, Thomas Cailly, Valérie Collot   +2 more
wiley   +1 more source

MOGAT3-mediated DAG accumulation drives acquired resistance to anti-BRAF/anti-EGFR therapy in BRAFV600E-mutant metastatic colorectal cancer

The Journal of Clinical Investigation
BRAFV600E-mutant metastatic colorectal cancer (mCRC) is associated with poor prognosis. The combination of anti-BRAF/anti-EGFR (encorafenib/cetuximab) treatment for patients with BRAFV600E-mutant mCRC improves clinical benefits; unfortunately, inevitable
Jiawei Wang, Huogang Wang, Wei Zhou, Xin Luo, Huijuan Wang, Qing Meng, Jiaxin Chen, Xiaoyu Chen, Yingqiang Liu, David W. Chan, Zhenyu Ju, Zhangfa Song   +11 more
doaj   +1 more source

Tumor-stroma interactions influence the response to PI3K targeted agents in preclinical models of colorectal cancer (CRC) [PDF]

, 2019
Introduction: One of the main obstacle to the successful development of therapeutic strategies remains the identification of biomarker underlying drug resistance. Recently, investigators have become more aware the role of the tumor microenvironment (TME)
Bazzichetto, Chiara
core  

NOS2/ARG1 axis and immune cell ratios as promising prognostic and predictive biomarkers for Cetuximab combined with chemotherapy in wt-KRAS human colorectal cancer

Frontiers in Immunology
BackgroundResistance to epidermal growth factor receptor monoclonal antibodies (anti-EGFR), such as cetuximab, remains a major therapeutic challenge. Growing evidence suggests that local tumor immune cells and systemic inflammation influence therapeutic ...
Djehane Houria Mataam, Assia Galleze, Sarra Benkhelifa, Ryad Trari, Wafa Khelaifia, Said Belhadef, Sabrina Bouhara, Sonia Ait Younes, Anissa Benali, Hassan Mahfouf, Olivier Morales, Olivier Morales, Houda Belguendouz, Nadira Delhem, Chafia Touil-Boukoffa, Hayet Rafa, Hayet Rafa   +16 more
doaj   +1 more source